论文部分内容阅读
下呼吸道感染的临床治疗以消除炎症、清除致病菌为主。近年来因青霉素类和一代头孢菌素类的耐药率逐年增高,而注射用三代头孢药费昂贵,因而门诊病人往往给予抗菌效果好、副作用少、给药方便的口服抗菌素。据对我院98年8月份贵重抗菌素消费流向统计分析所得,安奇、阿奇霉素和先力滕是下呼吸道抗菌治疗中用药频度较高的三种分属不同类型的口服抗菌素。现根据用药情况和疗效反馈对三种抗菌素治疗下呼吸道感染的临床疗效进行评估,并对其构成的不同给药方案,采用成本一效果分析方法(CEA,Cost-effectiveness analysis)进行浅议和评估。
Clinical treatment of lower respiratory tract infection in order to eliminate inflammation, mainly to eliminate pathogens. In recent years, due to penicillins and the generation of cephalosporins drug resistance increased year by year, while the injection of third-generation cephalosporins costly, so outpatients are often given antibacterial effect, less side effects, convenient oral administration of antibiotics. According to our hospital in August 98, the statistical analysis of the flow of expensive antibiotics from the statistical analysis, An Qi, azithromycin and the first force is the lower respiratory tract antibacterial therapy in the higher frequency of the three belong to different types of oral antibiotics. The clinical efficacy of the three antibiotics in the treatment of lower respiratory tract infection is evaluated according to the medication situation and the efficacy feedback. The different dosage regimens of the three kinds of antibiotics for the treatment of lower respiratory tract infection are discussed and evaluated by cost-effectiveness analysis (CEA) .